Camille L. Bedrosian - Jun 11, 2025 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role: Director
Signature: /s/ Tobin Schilke, as attorney-in-fact
Stock symbol: CRNX
Transactions as of: Jun 11, 2025
Transactions value $: $0
Form type: 4
Date filed: 6/13/2025, 04:30 PM
Previous filing: Apr 2, 2025
Next filing: Jun 23, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Bedrosian Camille L	Director	C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD, SAN DIEGO	/s/ Tobin Schilke, as attorney-in-fact	2025-06-13	0001326969

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRNX	Common Stock	Award	$0	+6.9K	+73.4%	$0.00	16.3K	Jun 11, 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRNX	Stock Option (right to buy)	Award	$0	+10.4K		$0.00	10.4K	Jun 11, 2025	Common Stock	10.4K	$32.33	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
F2	The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

Content

The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.